Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting
2024-04-08
AACR会议免疫疗法
CHICAGO and FORT WORTH, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, California.
The abstracts are currently available on the AACR meeting website. The posters will be available online at following the presentations.
Poster Presentation Details:
Abstract 4658 / 11: Genome wide CRISPR/Cas9 library screening identifies aurora kinase A as a regulator of elraglusib sensitivity in pancreatic cancer
Date/Time: Tuesday, April 9, 2024, 9:00 AM – 12:30 PM
New Compounds and Drug Targets
Presenter: Li Ding, Mayo Clinic, Rochester, MN
Location: Poster Section 27
Abstract 6426 / 5: Identification of potential immune biomarkers for GSK-3 inhibitorGSK-3 inhibitor elraglusib (9- ING-41) in patients with relapsed/refractory metastatic cancer
Date/Time: Tuesday, April 9, 2024, 1:30 PM – 5:00 PM
Session Predictive Biomarkers 6
Presenter: Taylor Weiskittel, Mayo Clinic, Rochester, MN
Location: Poster Section 44
About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high impact cancers. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitorGSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DDR pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at .
CONTACT:
Public Relations Dept.,
Actuate Therapeutics, Inc.
+1 (847) 986-4190
info@actuatetherapeutics.com
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。